Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of anti-PD-1/PD-L1/CTLA-4 immune checkpoint inhibi...

Full description

Saved in:
Bibliographic Details
Main Authors: Albert Jang, Jake N. Lichterman, Jeffrey Y. Zhong, Jonathan E. Shoag, Jorge A. Garcia, Tian Zhang, Pedro C. Barata
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Immunotherapy
gut microbiota
cytokine
interleukin
immune checkpoint inhibitor
vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629

Similar Items